A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/21/2016 |
| Start Date: | May 2008 |
| End Date: | June 2009 |
Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1
The primary purpose of this study is to evaluate the safety profile and tolerability of
single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
Inclusion Criteria:
- Chronically infected with HCV genotype 1
- Treatment naive or treatment non-responders or treatment intolerant
- HCV RNA viral load of ≥10*5* IU/mL
- BMI 18 to 35 kg/m²
Exclusion Criteria:
- Any significant acute or chronic medical illness which is not stable or is not
controlled with medication and not consistent with HCV infection
- Major surgery within 4 weeks of study drug administration and any gastrointestinal
surgery that could impact the absorption of study drug
- Co-infection with HIV or HBV
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Click here to add this to my saved trials